CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Traditional therapeutic approaches such as chemotherapy and radiation therapy have
burdened cancer patients with onerous physical and psychological challenges …

The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …

Recent advances in machine learning and experimental biology have offered breakthrough
solutions to problems such as protein structure prediction that were long thought to be …

Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

The recent success of cancer immunotherapies has highlighted the benefit of harnessing the
immune system for cancer treatment. Vaccines have a long history of promoting immunity to …

Interactions between T cell receptors (TCRs) and their cognate tumour antigens are central
to antitumour immune responses,–; however, the relationship between phenotypic …

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Immune evasion is a hallmark of cancer, enabling tumors to survive contact with the host
immune system and evade the cycle of immune recognition and destruction. Here, we …

Immunotherapy has revolutionized cancer treatment and substantially improved patient
outcome with regard to multiple tumour types. However, most patients still do not benefit …